anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There is a high level of evidence for improved disease control in head and neck cancer (HNC) using regimens with accelerated radiotherapy and concomitant chemotherapy. These intense regimens can result in severe acute and late side effect. The standard approach for documenting symptomatic adverse events (AEs) in cancer clinical trials involves investigator reporting using the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE). In Denmark, the Danish Head and Neck Cancer Group (DAHANCA) toxicity score has been used as an instrument in assessing objective treatment induced toxicity. New research in other cancer treatments indicate, that systematic patient assessment of side effects may improve treatment outcome. Patient Reported Outcomes (PROs) can be used for symptom monitoring. Interactive use of PRO may secure early recognition of specific symptoms in the individual patient and timely management of side effects.

This trial it is a prospective nationwide, single armed sequential cohort study will investigate the effects of active use of PROs in clinical counselling and decision making during primary or post-operative curative radiotherapy for squamous-cell carcinoma of the head and neck (HNSCC). It will investigate quality of life and the management of side effects in standard clinical counselling (control group) versus standard clinical counselling plus the PRO (PRO group). The EORTC QLQ-C30 (quality of life questionnaire) and EQ-D5-L5 will be answered in both groups. In the PRO group the participants will be asked to complete the electronic PRO (PRO CTCAE™ HNC relevant items supplemented by HNC specific items fra the EORTC library) weekly. The electronic PRO questionnaire is designed to give feedback to treating physician and nurses at visits during and shortly after radiotherapy.
Following various disease conditions such as trauma, orthopedic surgery, and infections etc., patients may be bedridden and unable to void in a bedpan or to make their way to the toilet. Others may be incontinent of urine. In such situations an indwelling catheter is often placed to relieve patients while they are incapacitated; in many cases a catheter is placed despite lack of urinary retention. Indwelling catheters, although effective, are associated with discomfort, pain, and urinary tract infections. In other cases diapers or absorbent pads may be used, or a condom-type urine collection device. These may be associated with skin irritation and infection.

The study will evaluate the UriCap-RM non-invasive urine collection device in hospitalized men.
Cell migration plays a pivotal role in various biological processes including cancer dissemination and successful metastasis, where the role of mechanical signals is increasingly acknowledged. This review focuses on the intricate mechanisms through which cancer cells modulate their migratory strategies via organelle adaptations in response to the extracellular matrix (ECM). Specifically, the nucleus and mitochondria emerge as pivotal mediators in this process. These organelles serve as sensors, translating mechanical stimuli into rapid metabolic alterations that sustain cell migration. Importantly, prolonged exposure to such stimuli can induce transcriptional or epigenetic changes, ultimately enhancing metastatic traits. Deciphering the intricate interplay between ECM properties and organelle adaptations not only advances our understanding of cytoskeletal dynamics but also holds promise for the development of innovative anti-metastatic therapeutic strategies.
Patients are encouraged to continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. A cognitive behavioral therapy approach to reinforce physical activity will be performed every 6 months.
The invention comprises compounds of the general formula <FORM:0928154/IV(a)/1> (wherein A represents an alkylene radical, R a di(C1-5 alkyl)-amino group or an alkyleneimino group which may be interrupted by a hetero atom, R1 a hydrogen or halogen atom or an alkyl or nitro group, R2 a hydrogen atom or an alkyl, aralkyl, alkanoyl, aroyl, alkoxycarbonyl or alkoxycarbonylalkyl group, and R3 a hydrogen atom or an alkoxy group) and their physiologically tolerable acid addition salts, and pharmaceutical preparations comprising these compounds in admixture or conjunction with a pharmaceutical carrier suitable for enteral, parenteral or topical administration. The compounds may be made by reacting an appropriate 2-phenylaminobenzimidazole, or a metal derivative thereof, with a reactive ester of an alcohol HO-A-R, or by reacting a 2-(R-A)-aminoaniline with a phenylcarbamic acid derivative (e.g. a diphenylurea, -thiourea, -S-substituted-isothiourea or -carbodiimide). If the product is one in which R2 is hydrogen, it may be treated to introduce a substituent corresponding to one of the other meanings given for R2, whilst a resulting acid addition salt may be converted into the free base or vice versa. S-Methyl-symdi-(p-alkoxyphenyl)- isothioureas are prepared by refluxing p-anisidine or p-phenetidine with carbon disulphide and sulphur in alcohol, and refluxing the resulting sym-di-(p-alkoxyphenyl)-thiourea with dimethyl sulphate in acetone. 2-(p- Methoxyphenylamino)- benzimidazole is prepared by heating o-phenylenediamine with S-methyl-sym-di-(p-methoxyphenyl)-isothiourea. Its N-acetyl derivative is prepared by boiling it with acetic anhydride and glacial acetic acid. The pharmaceutical preparations, which have analgesic and muscle relaxant action, may take the form of tablets, dragees, salves, creams, solutions, suspensions or emulsions.
All subjects received a standardised epidural solution containing 0.2% ropivacaine and 0.4（male）/0.3（famale）μg/ml sufentanil. The CEI group was infused continuously at a rate of （0.05\*kg）ml/h. The lockout time for both groups was 60 min.
This is an open label study, intended as a safety and efficacy assessment prior to a full comparator study. In this Phase I study, cells administered will be delivered in 6-10 intramyocardial injections that will be tested in 20 patients and 10 patients will be controls with a total of 30 HLHS patients.

A total of 30 patients with HLHS will be enrolled in a staged enrollment process. In this open-labeled study, a maximum of 20 patients will eventually receive intramyocardial injection of the allogeneic mesenchymal stem cells and 10 control patients with no cell injection. The enrollment of the patients will occur in two stages groups: Group A and Group B. In Group A, 10 consecutive HLHS patients will be initially enrolled in the allogenic MSCs treatment arm to determine feasibility and safety. After 6 months of the last enrolled patient in Group A, all Group A patients will be assessed in order to determine whether it is feasible and safe, including the harvesting, processing, and administering of the allogeneic MSCs. Thereafter, Group B will start enrolling a total of 20 HLHS patients which will be randomized to the treatment and control arms in a 1:1 ratio, respectively, in order to have 10 allogeneic MSCs-treated patient and 10 control patients. At the completion of this Phase I clinical study, the total enrolled cohort will be 20 patients treated with allogeneic MSCs and 10 patients in the control arm.
<P>PROBLEM TO BE SOLVED: To provide a propolis transformant capable of effectively exhibiting physiological action, such as anticancer action, to provide a method for producing the same, and to provide a health food.  <P>SOLUTION: This propolis transformant is given by transforming the propolis by utilizing bacidiomycetes and classified into a propolis fermented product and a propolis enzymatically-treated product. The propolis fermented product is produced by subjecting the propolis to fermentation treatment with mycelia of the bacidiomycetes and the propolis enzymatically-treated product is produced by subjecting the propolis to enzymatic treatment with an enzyme derived from the mycelia of the bacidiomycetes. The enzymatic treatment is preferably conducted by using a culture supernatant of the mycelia of the bacidiomycetes. The propolis preferably comprises an extract of the propolis, more preferably comprises an extract of the propolis with an alcohol, and furthermore preferably comprises an extract of the propolis with ethanol. The health food contains the propolis transformant.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Human α-defensins are inhibitors of interleukin-1β post transitional processing and release. Interleukin-1β is a key cytokine involved in the initiation and amplification of the inflammatory process, including the inflammation of diseases such as Crohn's Disease and Ulcerative Colitis. Particularly, human neutrophil defensin-1(HNP-1) produced mainly by neutrophils, and human α-defensin 5(HD-5) produced by Paneth cells has been found to block interleukin-1β post transitional processing and release. Thus, a pharmaceutical composition and method for treating inflammation in the mammalian tissues is herein disclosed. The pharmaceutical composition is a therapeutic supplementation of a metabolic pathway to reduce inflammation comprising a human α-defensins in a therapeutically effective amount or an amide, ester or salt thereof and a pharmaceutically effective carrier. The method for treating inflammation in mammalian tissues includes administering a human α-defensins to a mammal in an amount effective to inhibit the post translational processing and release of interleukin-1β.
This is a 12-week two arm pilot randomized control trial comparing two types of exercise interventions. Both groups will complete three 30-minute remote exercise sessions weekly, via Zoom delivered by a trained interventionist and supervised by a dedicated safety officer. Participants will be randomly assigned to either aerobic or balance based exercise for the duration of the study. Participants will sign informed consent in person during a baseline visit where measures of brain (magnetic resonance imaging \[MRI\] and electroencephalography \[EEG\]), cognition, patient reported outcomes and lifestyle questionnaires are collected. Participants will repeat this session in-person at the end of the 12-week intervention. Participants will wear a wrist-worn Actigraph for 7 consecutive days at 3 time points throughout the intervention period (once each month) to collect daily physical activity levels and sleep metrics. Both interventions will be individualized and progressive in terms of intensity and difficulty. The exercise interventions sessions will be thresholded at a heart rate of 80% symptom threshold assessed at baseline using a modified cycle and fitness test.
Clinical Presentation

Overdosage of SOMA commonly produces CNS depression. Death, coma, respiratory depression, hypotension, seizures, delirium, hallucinations, dystonic reactions, nystagmus, blurred vision, mydriasis, euphoria, muscular incoordination, rigidity, and/or headache have been reported with SOMA overdosage. Serotonin syndrome has been reported with carisoprodol intoxication. Many of the carisoprodol overdoses have occurred in the setting of multiple drug overdoses (including drugs of abuse, illegal drugs, and alcohol). The effects of an overdose of carisoprodol and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) can be additive even when one of the drugs has been taken in the recommended dosage. Fatal accidental and non-accidental overdoses of SOMA have been reported alone or in combination with CNS depressants.

Treatment of Overdosage

Basic life support measures should be instituted as dictated by the clinical presentation of the SOMA overdose. Vomiting should not be induced because of the risk of CNS and respiratory depression, and subsequent aspiration. Circulatory support should be administered with volume infusion and vasopressor agents if needed. Seizures should be treated with intravenous benzodiazepines and the reoccurrence of seizures may be treated with phenobarbital. In cases of severe CNS depression, airway protective reflexes may be compromised and tracheal intubation should be considered for airway protection and respiratory support. 

For decontamination in cases of severe toxicity, activated charcoal should be considered in a hospital setting in patients with large overdoses who present early and are not demonstrating CNS depression and can protect their airway.

For more information on the management of an overdose of SOMA, contact a Poison Control Center.
The invention discloses a Baoyuan effervescent tablet and a preparation method and application thereof, belonging to the technical field of food and medicines. Which comprises the following steps: main medicine, effervescent disintegrant and other auxiliary materials. The main drugs comprise: ginseng, astragalus, liquorice, cinnamon and ginger. Effervescent disintegrants include acid and base agents. Other adjuvants comprise surfactant, binder, sweetener, lubricant, etc. The effervescent tablet prepared by the invention overcomes the defects of original preparation of the Baoyuan decoction, and has good stability and dissolubility and high bioavailability. And has the characteristics of convenient taking, quick response, better taste, convenient carrying, transportation and storage and the like. In addition, the invention has better protection effect on a mouse low immunity model induced by cyclophosphamide. The traditional Chinese medicine belongs to medicinal and edible medicinal materials, is green, healthy and safe, can be applied to the field of food and medicine, and can be used as a medicinal and edible dual-purpose product to effectively enhance the body immunity of people with low immunity.
OBJECTIVE: To investigate the effect of spectacle correction on refractive progression in children with unilateral myopic anisometropia (UMA).
METHODS: In this retrospective study, 153 children with UMA (aged 8-12 years) were recruited and classified into an uncorrected (UC) group (n = 47) and a spectacle (SP) group (n = 106). The spherical equivalent refraction (SER) of the myopic eyes ranged from -0.75 to -4.00 D; the SER of the emmetropic eyes ranged from +1.00 to -0.25 D; anisometropia was ≥1.00 D and the follow-up duration was 1 year. Nineteen subjects from the SP group with follow-up records spanning at least 6 months before and after wearing spectacles were selected as a subgroup. Changes in the SER and axial length (AL), the degree of anisometropia and interocular AL differences of the two groups and the subgroup were analysed.
RESULTS: During the 1-year follow-up period, AL and SER changes in myopic eyes were significantly greater than those in emmetropic eyes in the UC group (p < 0.001). For the UC group, the degree of anisometropia and AL change increased (all p < 0.001). For the SP group, there were no significant differences in the degree of anisometropia or AL change (all p > 0.05). When comparing the groups, AL elongation of the myopic eyes in the UC group occurred significantly faster than in the SP group (p = 0.02), and AL elongation for the emmetropic eyes in the UC group occurred significantly slower than in the SP group (p = 0.04). For the subgroup, the AL and SER changes in the myopic eyes 6 months before wearing spectacles occurred significantly faster than those after correction (p < 0.001).
CONCLUSIONS: Spectacle correction could prevent increased anisometropia in uncorrected children with UMA by slowing myopia progression in the myopic eyes and accelerating the myopic shift in the contralateral eye.
Intervention: Perskindol Dolo Gel is a topical product with a warming effect. In a single application 3g of the product is applied in an area of 10cm x 10cm on the unilateral lumbar back until it has been completely absorbed by the skin.
The placebo product will be identical to the active product in taste and appearance and include Vitamin D3 but without the L. reuteri. Administration twice daily.
Adolescents assigned to receive ASMA 2.0 will receive all seven modules over the two month trial, completing one module per week. Adolescents will be assigned one module per week, but will have free access to all completed modules for the duration of the two-month trial. Each module is expected to take between 30-40 minutes to complete, although adolescents will be able to engage with the software for as long as desired.
The invention provides a method of screening a substance for the ability to effect the formation of a retinoid X receptor homodimer comprising combining the substance and a solution containing retinoid X receptors and determining the presence of homodimer formation. Also provided is a method of screening a substance for an effect on a retinoid X receptor homodimer's ability to bind DNA comprising combining the substance with the homodimer and determining the effect of the compound on the homodimer's ability to bind DNA. A method of inhibiting an activity of a retinoid X receptor heterodimer comprising increasing the formation of a retinoid X receptor homodimer, thereby preventing the retinoid X receptor from forming a heterodimer and preventing the resulting heterodimer activity is also provided. A method of inhibiting an activity of a retinoid X receptor homodimer is also provided. A method of determining an increased probability of a pathology associated with retinoid X receptor homodimer formation and treating such pathology are further provided. In addition, a method of screening a response element for binding with a retinoid X receptor homodimer is provided. Finally, the invention provides methods of activating retinoid X receptor homodimer formation.
BACKGROUND: Plasmodium vivax is the main causative agent of malaria in Panama. However, the prevalence of asymptomatic infections in the different endemic regions remains unknown. Understanding the epidemiological behavior of asymptomatic infections is essential for the elimination of malaria. This study aimed to determine the prevalence of asymptomatic malarial infections in one of the main endemic regions of Panama using multiplex real-time reverse transcription RT-MqPCR.
METHODS: A cross-sectional study was conducted in three communities in the Guna Yala Comarca. A total of 551 thick blood smears and their respective samples on filter paper were collected from volunteers of different ages and sexes from June 20 to 25, 2016. Infections by the Plasmodium spp. were diagnosed using microscopy and RT-MqPCR. All statistical analyses were performed using the R software.
RESULTS: The average prevalence of asymptomatic infections by P. vivax in the three communities detected by RT-MqPCR was 9.3%, with Ukupa having the highest prevalence (13.4%), followed by Aidirgandi (11.1%) and Irgandi (3.3%). A total of 74 samples were diagnosed as asymptomatic infections using RT-MqPCR. Light microscopy (LM) detected that 17.6% (13/74) of the asymptomatic samples and 82.4% (61/74) were diagnosed as false negatives. A 100% correlation was observed between samples diagnosed using LM and RT-MqPCR. A total of 52.7% (39/74) of the asymptomatic patients were female and 85.1% (63/74) were registered between the ages of 1 and 21 years. Factors associated with asymptomatic infection were community (aOR = 0.38 (95% CI 0.17-0.83), p < 0.001) and age aOR = 0.98 (95% CI 0.97-1.00), p < 0.05); F = 5.38; p < 0.05).
CONCLUSIONS: This study provides novel evidence of the considerable prevalence of asymptomatic P. vivax infections in the endemic region of Kuna Yala, representing a new challenge that requires immediate attention from the National Malaria Program. The results of this study provide essential information for the health authorities responsible for developing new policies. Furthermore, it will allow program administrators to reorient and design effective malaria control strategies that consider asymptomatic infections as a fundamental part of malaria control and move towards fulfilling their commitment to eliminate it.
PURPOSE: To obtain a cosmetic containing silicone-treated zinc oxide and a composite powdery material, having an excellent sebum-controlling property, good in touch and not having oily touch. CONSTITUTION: A cosmetic contains a powdery material (e.g. spherical nylon powder) and a sebum-resistant powdery material produced by treating the surface of zinc oxide with methylhydrogensiloxane-dimethylsiloxane copolymer of the formula [m:n is (0.6-1.4):1; m+n=20-60]. The surface-treated sebum- resistant powdery material and the powdery material are used in a weight ratio of 5/95 to 60/40, and the composite powdery material is contained in an amount of 0.01-60wt.% based on the whole amount of the cosmetic. An oil- absorbing powdery material (e.g. a clay mineral) may be added to the cosmetic for the improvement in the sebum-fixing ability of the cosmetic. The silicone treatment of the zinc oxide is performed by heating the mixed raw materials at 50-200 deg.C for 0.5-5hrs. Thus, the cosmetic prevented in oily touch and in brightness and good in durability is obtained.
Symptoms of anorexia, nausea, and vomiting are the most frequently noted of all toxic reactions. Over 90% of patients are affected with the initial few doses. The vomiting lasts 1 to 12 hours and is incompletely and unpredictably palliated with phenobarbital and/or prochlorperazine. Rarely, intractable nausea and vomiting have necessitated discontinuance of therapy with dacarbazine for injection. Rarely, dacarbazine for injection has caused diarrhea. Some helpful suggestions include restricting the patient's oral intake of food for 4 to 6 hours prior to treatment. The rapid toleration of these symptoms suggests that a central nervous system mechanism may be involved, and usually these symptoms subside after the first 1 or 2 days.

There are a number of minor toxicities that are infrequently noted. Patients have experienced an influenza-like syndrome of fever to 39°C, myalgias and malaise. These symptoms occur usually after large single doses, may last for several days, and they may occur with successive treatments.

Alopecia has been noted as has facial flushing and facial paresthesia. There have been few reports of significant liver or renal function test abnormalities in man. However, these abnormalities have been observed more frequently in animal studies.

Erythematous and urticarial rashes have been observed infrequently after administration of dacarbazine for injection. Rarely, photosensitivity reactions may occur.

To report SUSPECTED ADVERSE REACTIONS, contact Meitheal Pharmaceuticals, Inc. at 1-844-824-8426 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
<P>PROBLEM TO BE SOLVED: To provide an oral preparation in which even strong bitter taste of isosorbide can be effectively alleviated by a small amount of a sweetener, its production method and a method for alleviating the bitter taste.  <P>SOLUTION: The oral preparation contains a first sweetener (aspartame) of 0.01 to 0.5 parts by weight, a second sweetener (sodium saccharin or the like) of 0.1 to 2 parts by weight and an acidulant (lactic acid, malic acid, tartaric acid, citric acid, fumaric acid or the like), based on isosorbide of 100 parts by weight, wherein the amount of the second sweetener is 2 to 20 parts by weight relative to 1 part by weight of the first sweetener. The amount of the acidulant is 0.1 to 10 parts by weight relative to 1 part by weight of the total amount of the sweeteners. The oral preparation may contain a sweetener-reinforcing agent (sodium chloride and the like) having salty taste, a tasty ingredient and/or a perfume. The oral preparation may take a form of a liquid, a jelly, a gummy material and the like and may have a pH of 2 to 5.5.  <P>COPYRIGHT: (C)2006,JPO&NCIPI